Inventor

UMAÑA PABLO

CH33 patents

⚠️ This page may combine multiple inventors who share the name “UMAÑA PABLO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

UMAÑA PABLO

HOFFMANN LA ROCHE

Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9

Tumor-targeted agonistic CD28 antigen binding molecules

Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists

Antibodies binding to CD3 and CD19

Bispecific antibody molecules binding to CD3 and TYRP-1

Bispecific antibody molecules binding to CD3 and EGFRvIII

Antibodies binding to HLA-A2/WT1

Antibodies binding to CD3 and CD19

Bispecific antibody molecules binding to CD3 and EGFRvIII

Antibodies binding to HLA-A2/WT1

Bispecific antigen binding molecule for a costimulatory TNF receptor

Bispecific antigen binding molecule for a costimulatory TNF receptor

Antibodies binding to HLA-A2/MAGE-A4

Agonistic CD28 antigen binding molecules targeting Her2

Combination therapy with targeted 4-1BB (CD137) agonists/anti-FAP binding domain and anti-CEA/anti-CD3 bispecific antibody

Bispecific antigen binding molecules capable of specific binding to CD40 and to fap

ROCHE GLYCART AG

Fc-free antibodies comprising two fab-fragments and methods of use

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

UMAÑA PABLO

Antigen binding molecules with increased Fc receptor binding affinity and effector function

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function

Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof

MÖSSNER EKKEHARD

Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof

Targeted immunoconjugates

BACAC MARINA

Anti-FAP antibodies and methods of use

FREIMOSER-GRUNDSCHOBER ANNE

Anti-tenascin-C A2 antibodies and methods of use